CY1115863T1 - Ενωσεις τριαζολοπyριδινης - Google Patents

Ενωσεις τριαζολοπyριδινης

Info

Publication number
CY1115863T1
CY1115863T1 CY20141100951T CY141100951T CY1115863T1 CY 1115863 T1 CY1115863 T1 CY 1115863T1 CY 20141100951 T CY20141100951 T CY 20141100951T CY 141100951 T CY141100951 T CY 141100951T CY 1115863 T1 CY1115863 T1 CY 1115863T1
Authority
CY
Cyprus
Prior art keywords
triazolopyridine compounds
compounds
triazolopyridine
medicaments
formula
Prior art date
Application number
CY20141100951T
Other languages
English (en)
Inventor
Alexander Flohr
Luca Gobbi
Zbinden Katrin Groebke
Matthias Koerner
Jens-Uwe Peters
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of CY1115863T1 publication Critical patent/CY1115863T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Η εφεύρεση αφορά ενώσεις τριαζολοπυριδίνης του τύπου (I), όπου τα R1, R2, R3 και R4 είναι όπως ορίζονται στην περιγραφή και τις αξιώσεις, καθώς και με φυσιολογικώς αποδεκτά άλατα αυτών. Αυτές οι ενώσεις αναστέλλουν το PDE 10Α και μπορούν να χρησιμοποιηθούν ως φάρμακα.
CY20141100951T 2010-12-07 2014-11-14 Ενωσεις τριαζολοπyριδινης CY1115863T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10194014 2010-12-07
EP11791543.9A EP2649070B1 (en) 2010-12-07 2011-12-05 Triazolopyridine compounds

Publications (1)

Publication Number Publication Date
CY1115863T1 true CY1115863T1 (el) 2017-01-25

Family

ID=45099086

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100951T CY1115863T1 (el) 2010-12-07 2014-11-14 Ενωσεις τριαζολοπyριδινης

Country Status (30)

Country Link
US (1) US8349824B2 (el)
EP (1) EP2649070B1 (el)
JP (1) JP5932828B2 (el)
KR (1) KR20130128426A (el)
CN (1) CN103237803B (el)
AR (1) AR084152A1 (el)
AU (1) AU2011340685A1 (el)
BR (1) BR112013013912A2 (el)
CA (1) CA2816829C (el)
CL (1) CL2013001591A1 (el)
CO (1) CO6741154A2 (el)
CR (1) CR20130239A (el)
CY (1) CY1115863T1 (el)
DK (1) DK2649070T3 (el)
EA (1) EA022607B1 (el)
EC (1) ECSP13012667A (el)
ES (1) ES2520647T3 (el)
HR (1) HRP20141200T1 (el)
IL (1) IL225969A0 (el)
MA (1) MA35086B1 (el)
MX (1) MX2013006054A (el)
PE (1) PE20140226A1 (el)
PL (1) PL2649070T3 (el)
PT (1) PT2649070E (el)
RS (1) RS53677B1 (el)
SG (1) SG190305A1 (el)
SI (1) SI2649070T1 (el)
UA (1) UA109037C2 (el)
WO (1) WO2012076430A1 (el)
ZA (1) ZA201303811B (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2757883B1 (en) * 2011-09-22 2021-01-13 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
US20140235667A1 (en) 2011-09-22 2014-08-21 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
RU2620379C2 (ru) 2012-02-09 2017-05-25 Ф.Хоффманн-Ля Рош Аг СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ 2-ФЕНИЛ[1,2,4]ТРИАЗОЛО[1,5-а]ПИРИДИНА
BR112015017674A2 (pt) * 2013-01-31 2017-07-11 Hoffmann La Roche compostos rádio marcados
AU2014221799B2 (en) * 2013-02-27 2017-09-28 Mochida Pharmaceutical Co., Ltd. Novel pyrazole derivative
HUE032407T2 (en) 2013-04-30 2017-09-28 Hoffmann La Roche Plasma catalyzed coupling of pyrazolamides
EP3006444B1 (en) * 2013-05-31 2017-09-27 Nissan Chemical Industries, Ltd. Heterocyclic amide compound
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
EP3176168A4 (en) * 2014-07-30 2018-05-02 Mochida Pharmaceutical Co., Ltd. Pyrazole derivative manufacturing method
WO2016017711A1 (ja) * 2014-07-30 2016-02-04 持田製薬株式会社 ピラゾール誘導体の製造方法
WO2020021024A1 (en) * 2018-07-26 2020-01-30 Phenex Pharmaceuticals Ag Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
IL298713A (en) 2020-06-05 2023-02-01 Noema Pharma Ag Use of a phosphodiesterase 10 inhibitor to treat Tourette syndrome
CA3206573A1 (en) * 2021-01-28 2022-08-04 George GARIBALDI Methods for the treatment of childhood-onset fluency disorder

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032404A1 (en) 2003-07-31 2007-02-08 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為pde10a酵素抑制劑之新穎苯基咪唑衍生物

Also Published As

Publication number Publication date
CA2816829C (en) 2018-12-04
AU2011340685A1 (en) 2013-05-23
EA022607B1 (ru) 2016-01-29
UA109037C2 (uk) 2015-07-10
CA2816829A1 (en) 2012-06-14
BR112013013912A2 (pt) 2016-09-13
PT2649070E (pt) 2014-11-21
ECSP13012667A (es) 2013-08-30
EP2649070B1 (en) 2014-09-17
AR084152A1 (es) 2013-04-24
US8349824B2 (en) 2013-01-08
KR20130128426A (ko) 2013-11-26
JP2013544859A (ja) 2013-12-19
MX2013006054A (es) 2013-06-18
CR20130239A (es) 2013-06-27
SG190305A1 (en) 2013-06-28
PE20140226A1 (es) 2014-03-08
MA35086B1 (fr) 2014-05-02
US20120142665A1 (en) 2012-06-07
JP5932828B2 (ja) 2016-06-08
DK2649070T3 (da) 2014-10-13
EA201390799A1 (ru) 2013-12-30
ZA201303811B (en) 2014-04-30
HRP20141200T1 (hr) 2015-02-13
CN103237803A (zh) 2013-08-07
ES2520647T3 (es) 2014-11-11
CL2013001591A1 (es) 2013-12-27
WO2012076430A1 (en) 2012-06-14
SI2649070T1 (sl) 2014-12-31
CN103237803B (zh) 2016-04-13
PL2649070T3 (pl) 2015-03-31
CO6741154A2 (es) 2013-08-30
RS53677B1 (en) 2015-04-30
EP2649070A1 (en) 2013-10-16
IL225969A0 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
CY1115863T1 (el) Ενωσεις τριαζολοπyριδινης
CY1119953T1 (el) Yποκατεστημενες πυριδοπυραζινες ως προτυποι syk ανοστολεις
CY1122585T1 (el) Συνδυασμοι που περιλαμβανουν παραγωγα 5-φαινοξυ-3η-πυριμιδιν-4-ονης και η χρηση αυτων για την προφυλαξη ή αγωγη λοιμωξης απο ηiv
CY1114764T1 (el) Παραγωγα προλινης ως αναστολεις καθεψινης
CY1115945T1 (el) Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση
CY1120031T1 (el) Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης
CY1116120T1 (el) Παραγωγα ιμιδαζοπυριδινης ή ιμιδαζοπυριμιδινης ως αναστολεις φωσφοδιεστερασης 10α
CY1117878T1 (el) Πυριδινo-2-αμιδια χρησιμα ως αγωνιστες του cb2
CY1118735T1 (el) Παραγωγα βενζιμιδαζολο-προλινης
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
CY1114793T1 (el) Παραγωγα αμινοπυραζολιου
CY1117147T1 (el) Παραγωγα [1,2,3]τριαζολο[4,5-d]πυριμιδiνης ως αγωνιστες του κaνναβινοειδους υποδοχεα 2
CY1117956T1 (el) N3-αντικατεστημενα-n1-sulfonyl-5-fluoropyrimidinone παραγωγα
CY1116984T1 (el) ΠΑΡΑΓΩΓΑ [1,2,3]ΤΡΙΑΖΟΛΟ[4,5-d]ΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΓΩΝΙΣΤΕΣ ΥΠΟΔΟΧΕΑ ΚΑΝΝΑΒΙΝΟΕΙΔΩΝ 2
CY1117105T1 (el) Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao
CY1118950T1 (el) Νεα παραγωγα πυραζολιου
CY1119619T1 (el) Παραγωγα πυριδιν-4-υλιου
CY1115301T1 (el) Παραγωγα ισοξαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου
CY1118662T1 (el) Νεες δικυκλικες πυριδινονες
NI201200191A (es) Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
CR20150250A (es) Nuevos derivados de piridina
CY1114759T1 (el) Παραγωγα πυριδιν-4-υλι0υ ως s1p1/edg1 αγωνιστες
CY1118593T1 (el) Πρωτοτυπα παραγωγα πυραζινης
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
UA116395C2 (uk) ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ